Apimeds Pharmaceuticals US financials
$5.02−21.44%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — |
| Operating income | -$6.3M | -$12.2M | -$7.0M | -$1.8M | -$2.7M |
| Net income | -$20.2M | -$35.1M | -$1.2M | -$1.8M | -$2.7M |
| Net margin | — | — | — | — | — |
| Diluted EPS | $-11.77 | $-2.26 | $-0.05 | $-1.40 | $-2.57 |
| EBITDA | -$6.3M | -$12.2M | -$7.0M | -$1.8M | -$2.7M |
| Operating cash flow | -$5.7M | -$2.1M | -$3.8M | -$1.7M | -$3.4M |
| Free cash flow | -$5.7M | -$2.1M | -$3.8M | -$1.7M | -$3.4M |
| Diluted shares | 1.7M | 15.5M | 22.0M | 1.3M | 1.0M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 |
|---|---|---|---|---|---|
| Cash & equivalents | $278.4K | $979.5K | $1.6M | $7.0M | $8.7M |
| Short-term investments | $0.00 | $1.5M | $2.0M | $0.00 | $0.00 |
| Total debt | $8.9M | $7.9M | $7.1M | $0.00 | $0.00 |
| Total assets | $127.6M | $141.2M | $164.2M | $9.3M | $10.5M |
| Total liabilities | $21.2M | $14.7M | $10.8M | $1.1M | $809.0K |
| Shareholders' equity | $106.4M | $126.5M | $153.3M | $8.2M | $9.7M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology